Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - procarbazine hydrochloride, quantity: 58.3 mg (equivalent: procarbazine, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; iron oxide yellow; magnesium stearate; titanium dioxide; purified talc; mannitol; maize starch - indications as at 23 august 1991: treatment of hodgkin's disease (multiple lymphadenoma); treatment of other malignant lymphomas including lymphosarcoma, reticulosarcoma, brill-symmers disease. natulan is dissimilar to other cytostatic agents and may be effective in cases resistant to other drugs and x-rays.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - aminolevulinic acid hydrochloride, quantity: 10.2 mg (equivalent: aminolevulinic acid, qty 8 mg) - patch, dermal - excipient ingredients: polyethylene terephthalate; polyethylene; aluminium; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - treatment of mild to moderate actinic keratoses (ak) lesions on the face and scalp (hairless areas).

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: disodium edetate; water for injections; sodium hydroxide - antidote for paracetamol poisoning. ,acetylcysteine is indicated in the treatment of paracetamol overdose to protect against hepatotoxity.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; silicon dioxide; microcrystalline cellulose - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 25 mg - tablet, uncoated - excipient ingredients: silicon dioxide; magnesium stearate; microcrystalline cellulose; maize starch - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - amifostine, quantity: 500 mg - injection, powder for - excipient ingredients: - to decrease the incidence of neutropenia related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum-containing drugs); decrease in the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and the provision of better adherence to these types of chemotherapy regimens. indications as at 31 march 2000: ethyol is indicated to decrease the incidence of neutropenia-related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum containing drugs); decrease the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and to provide better adherence to these types of chemotherapy regimens. ethyol is also indicated to protect against acute and late xerostomia associated with standard fractionated radiation therapy in patients with head and neck cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - chloramphenicol sodium succinate (equivalent: chloramphenicol, qty 1 g) - injection, powder for - excipient ingredients: - chloromycetin succinate is specifically indicated for bacterial meningitis, typhoid fever, rickettsial infections, intra ocular infections, other serious infections where bacteriological evidence or clinical judgement indicates that chloramphenicol is appropriate antibiotic.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - colistimethate sodium (equivalent: colistin, qty iu) - injection, powder for - excipient ingredients: - colistin link parental is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitve strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus and neisseria. colistin link parental has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. pending results of appropriate bacterialogic cultures and sensitvity tests, colistin link parental may be used to initiate therapy in serious infections that are suspected due to gram-negative organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - interferon gamma-1b, quantity: 4 million iu/ml - injection, solution - excipient ingredients: succinic acid; sodium succinate hexahydrate; mannitol; water for injections; polysorbate 20 - as an adjunct for reduction of the frequency of serious infections in patients with chronic granulomatous disease (cgd). the benefits of imukin have been most marked in children with cgd although imukin may be used in adult patients.